The bill adds a clarification to 21 U.S.C. 863 (Section 422 of the Controlled Substances Act) stating that the statute does not apply to equipment whose intended use is to indicate the presence of fentanyl or xylazine in a compound. In short, possession, sale, purchase, importation, exportation, or transportation of such testing equipment would not be unlawful under that section of the CSA.
This is significant because ambiguity in federal law and enforcement has chilled distribution and use of rapid-test strips and other field tests that detect fentanyl and xylazine. The change aims to remove criminal or seizure risk for manufacturers, distributors, harm-reduction programs, and individuals who provide or use these tests, potentially expanding access to tools that inform safer use and overdose prevention efforts.
At a Glance
What It Does
The bill amends Section 422 (21 U.S.C. 863) by adding a subsection clarifying that the statute does not cover equipment intended to indicate the presence of fentanyl or xylazine. It specifically protects possession, sale, purchase, importation, exportation, and transportation of that equipment from liability under that section.
Who It Affects
Manufacturers, importers, distributors, retailers, harm-reduction organizations, public-health programs, testing laboratories, and individuals who carry or distribute fentanyl/xylazine test kits are directly affected. Federal enforcement agencies and customs authorities will need to adjust enforcement and seizure practices.
Why It Matters
The change reduces legal uncertainty that has limited availability and cross-border movement of test kits, which harm-reduction groups use to detect deadly adulterants. It also establishes a narrow federal carve-out that could influence how agencies prioritize seizures and prosecutions related to drug-testing paraphernalia.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill inserts a single clarifying paragraph into the Controlled Substances Act: equipment designed to indicate whether a compound contains fentanyl or xylazine is not governed by 21 U.S.C. 863. That statutory section has been used to target tools or equipment associated with drug production and distribution; this amendment says plainly those tools for testing presence of these two substances aren’t covered.
The protection reaches the full chain of movement—possession, sale, purchase and cross-border transport.
The operative phrase in the new text is about the equipment’s “intended use.” That puts focus on the purpose stated or demonstrated by the seller, buyer, or user—rather than on the physical characteristics of the device alone. In practice, enforcement will look at marketing, labeling, training materials, distribution channels, and how organizations use the equipment to determine whether the exemption applies.The bill is narrowly tailored to two substances: fentanyl and xylazine.
It does not reclassify those substances, change criminal penalties for drug possession or trafficking, or establish federal standards for test accuracy, certification, or labeling. Nor does it provide federal funding or a regulatory pathway; it only narrows the reach of Section 422 as applied to testing equipment for those two drugs.Operationally, the amendment should reduce the risk that Customs and Border Protection or other federal agencies seize shipments of test strips or that distributors face prosecution under 21 U.S.C. 863.
However, because the law remains unchanged on other paraphernalia and because state-level paraphernalia statutes are unaffected by federal carve-outs, organizations that distribute kits will still need to manage state-by-state compliance and potential civil-liability exposure from inaccurate tests.
The Five Things You Need to Know
The bill adds subsection (g) to Section 422 of the Controlled Substances Act (21 U.S.C. 863) to create the exclusion.
The exclusion applies when the equipment’s intended use is to indicate the presence of fentanyl or xylazine, placing emphasis on purpose rather than device form.
Protected activities are explicit: possession, sale, purchase, importation, exportation, and transportation are all covered by the exemption.
The protection is substance-specific: it covers tests for fentanyl and xylazine only, not general drug-testing equipment for other drugs or adulterants.
The bill does not set accuracy, labeling, approval, or funding requirements—nor does it change controlled-substance scheduling or state-level paraphernalia laws.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Gives the act two short titles: the Safeguarding Testing and Overdose Prevention Against Fentanyl and Xylazine Act and the STOP Fentanyl and Xylazine Act. This is purely nominal but frames legislative intent toward public-health and harm-reduction goals.
Subsection (g) — carve-out for fentanyl and xylazine test equipment
Adds a new subsection that expressly states Section 422 does not apply to equipment intended to indicate fentanyl or xylazine presence. Practically, this prevents prosecutors from relying on Section 422 to charge or seize tools whose marketed and demonstrable purpose is detection of those two substances. The language covers a broad set of activities—possession through international movement—so commercial importers and non‑profit distributors gain protection across the supply chain.
Intended-use standard and enforcement implications
Because the exemption depends on ‘‘intended use,’’ courts and agencies will look to secondary evidence—advertising, packaging, training materials, distribution patterns, and purchaser behavior—to decide whether a particular item qualifies. That shifts many cases from a bright‑line product test to a fact‑intensive inquiry, which favors manufacturers and health programs that clearly document legitimate testing purposes but leaves ambiguity where marketing or distribution mixes test tools with other paraphernalia.
This bill is one of many.
Codify tracks hundreds of bills on Justice across all five countries.
Explore Justice in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Harm‑reduction organizations and syringe‑exchange programs — They can carry, distribute, and import fentanyl/xylazine test strips and kits with reduced federal prosecution and seizure risk, improving outreach and point‑of‑use testing.
- Manufacturers and importers of test equipment — They face lower legal exposure for making and shipping kits that explicitly detect fentanyl or xylazine, which expands U.S. market access and supply chains.
- Public‑health agencies and community clinics — Easier procurement and distribution of test kits supports overdose-prevention programs, surveillance, and targeted messaging in high‑risk communities.
- Retailers and pharmacies that stock test strips — Retail channels can offer these products without the same federal Section 422 risk, broadening consumer access.
- People who use drugs — Greater availability of field tests may enable safer decision‑making at point of use and lead to reduced overdose incidents involving fentanyl or xylazine.
Who Bears the Cost
- Federal enforcement and customs agencies (DEA, CBP) — They will need to update guidance, training, and seizure practices and may face narrower grounds for interdiction related to testing equipment.
- State and local prosecutors or legislatures — State paraphernalia statutes remain in force; some jurisdictions may need to revise laws or face increased political pressure, creating legislative and enforcement costs.
- Manufacturers and distributors — While the bill reduces Section 422 risk, companies gain no federal quality or liability shield; they may face product‑liability suits if tests are inaccurate and cause harm.
- Small vendors and platforms — Rapid market entry by larger suppliers could compress margins for smaller specialist providers who shoulder compliance burdens.
- Nonprofit distributors — Scaling distribution may require new logistics, training, and recordkeeping to demonstrate ‘‘intended use’’ and avoid residual enforcement risk.
Key Issues
The Core Tension
The bill balances two legitimate aims—expanding access to life‑saving detection tools and preserving law‑enforcement capacity to disrupt drug distribution—but does so by narrowing a criminal statute without adding quality controls or harmonizing state laws. That creates a trade‑off: greater availability of tests may reduce overdoses, yet the lack of federal standards and the reliance on an evidentiary ‘‘intended use’’ test risks uneven implementation, consumer confusion, and litigation over both enforcement and product liability.
The bill solves a narrow legal problem—clarifying that Section 422 does not apply to equipment intended to detect fentanyl or xylazine—but it leaves many practical and legal questions unresolved. The ‘‘intended use’’ test central to the exemption is inherently fact‑specific: labeling, marketing, sales channels, and purchaser conduct will all inform enforcement decisions.
Organizations distributing kits should document legitimate public‑health uses to reduce interpretive risk, but that documentation does not create an absolute safe harbor.
The statute is silent on accuracy, quality control, or consumer protections. It removes the threat of Section 422 enforcement but does not require manufacturers to meet any federal testing standard, nor does it protect them from civil suits alleging harm from false negatives or false positives.
The exemption is also narrowly substance‑specific; it excludes only fentanyl and xylazine tests, leaving other adulterants or multi‑drug test devices in legal limbo. Finally, the bill amends federal law only: state paraphernalia statutes, which often carry independent penalties and seizure authority, remain a parallel compliance hurdle for distributors and users alike.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.